Japan's Ministries Promote Industry-Academic Alliances
This article was originally published in PharmAsia News
To encourage collaboration between the pharmaceutical industry and academia, Japan's Ministry of Economy, Trade and Industry and Ministry of Education, Culture, Sports, Science and Technology are arranging a matching session in Tokyo at the end of March. Leading research facilities in the field, such as Kyodo University, Tokyo University, Keio and Rikagaku Institute, will present their latest research results and pharmaceutical companies and medical device makers will attend to learn more about potential collaborations. The ministries intend to continue the sessions, with the hope that industry-academic alliances will provide Japan a competitive edge in research and intellectual property. (Click here for more - Japanese language
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.